APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Medical Nuclide Products

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Medical Nuclide Products Market Outlook and Growth Opportunities 2026

Report ID 174011010423 December 2025213 pages

Choose your research edition.

Industry ResearchMedical Nuclide Products Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Medical Nuclide Products Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Medical Nuclide Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medical Nuclide Products Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Medical Nuclide Products Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Medical Nuclide Products market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Medical Nuclide Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Medical Nuclide Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medical Nuclide Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Medical Nuclide Products market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Medical Nuclide Products market include China Isotope & Radiation, Dongcheng Pharma, Eli Lilly, Junan Pharmaceutical, Bayer, Siemens, Q BioMed, Progenics Pharmaceuticals and Polatom, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Medical Nuclide Products market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Medical Nuclide Products and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Medical Nuclide Products revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Medical Nuclide Products market.

Medical Nuclide Products Segment by Company

China Isotope & Radiation

Dongcheng Pharma

Eli Lilly

Junan Pharmaceutical

Bayer

Siemens

Q BioMed

Progenics Pharmaceuticals

Polatom

NTP Radioisotopes

NRG

Novartis International AG

Nordion

Mundipharma

Monrol

Lantheus Medical Imaging, Inc.

Jubilant Life Sciences

International Isotopes

GE Healthcare

Eckert & Ziegler Strahlen

Curium Pharma

Cardinal Health

Bracco Imaging

Aurobindo Pharma

ANSTO

Acrotech Biopharma.

Medical Nuclide Products Segment by Type

Radiopharmaceuticals

Radioactive Sources

Medical Diagnostic Nuclides

Others

Medical Nuclide Products Segment by Application

Hematological Diseases

Cardiovascular Diseases

Bone and Joint Diseases

Cancer

Others

Medical Nuclide Products Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Medical Nuclide Products status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Medical Nuclide Products key companies, revenue, market share, and recent developments.

3. To split the Medical Nuclide Products breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Medical Nuclide Products market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Medical Nuclide Products significant trends, drivers, influence factors in global and regions.

6. To analyze Medical Nuclide Products competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medical Nuclide Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medical Nuclide Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medical Nuclide Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medical Nuclide Products industry.

Chapter 3: Detailed analysis of Medical Nuclide Products company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Medical Nuclide Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Medical Nuclide Products in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Medical Nuclide Products Industry Trends Table 2. Medical Nuclide Products Industry Drivers Table 3. Medical Nuclide Products Industry Opportunities and Challenges Table 4. Medical Nuclide Products Industry Restraints Table 5. Global Medical Nuclide Products Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Medical Nuclide Products Revenue Share by Company (2021-2026) Table 7. Global Medical Nuclide Products Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Medical Nuclide Products Key Company Manufacturing Base & Headquarters Table 9. Global Medical Nuclide Products Company, Product Type & Application Table 10. Global Medical Nuclide Products Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Medical Nuclide Products by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Radiopharmaceuticals Table 15. Significant Companies of Radioactive Sources Table 16. Significant Companies of Medical Diagnostic Nuclides Table 17. Significant Companies of Others Table 18. Global Medical Nuclide Products Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Medical Nuclide Products Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Medical Nuclide Products Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Medical Nuclide Products Sales Value Share by Type (2021-2026) Table 22. Global Medical Nuclide Products Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hematological Diseases Table 24. Significant Companies of Cardiovascular Diseases Table 25. Significant Companies of Bone and Joint Diseases Table 26. Significant Companies of Cancer Table 27. Significant Companies of Others Table 28. Global Medical Nuclide Products Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Medical Nuclide Products Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Medical Nuclide Products Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Medical Nuclide Products Sales Value Share by Application (2021-2026) Table 32. Global Medical Nuclide Products Sales Value Share by Application (2027-2032) Table 33. Global Medical Nuclide Products Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Medical Nuclide Products Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Medical Nuclide Products Sales Value Share by Region (2021-2026) Table 36. Global Medical Nuclide Products Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Medical Nuclide Products Sales Value Share by Region (2027-2032) Table 38. Global Medical Nuclide Products Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Medical Nuclide Products Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Medical Nuclide Products Sales Value Market Share by Country (2021-2026) Table 41. Global Medical Nuclide Products Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Medical Nuclide Products Sales Value Market Share by Country (2027-2032) Table 43. China Isotope & Radiation Company Information Table 44. China Isotope & Radiation Business Overview Table 45. China Isotope & Radiation Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. China Isotope & Radiation Medical Nuclide Products Product Portfolio Table 47. China Isotope & Radiation Recent Development Table 48. Dongcheng Pharma Company Information Table 49. Dongcheng Pharma Business Overview Table 50. Dongcheng Pharma Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Dongcheng Pharma Medical Nuclide Products Product Portfolio Table 52. Dongcheng Pharma Recent Development Table 53. Eli Lilly Company Information Table 54. Eli Lilly Business Overview Table 55. Eli Lilly Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Eli Lilly Medical Nuclide Products Product Portfolio Table 57. Eli Lilly Recent Development Table 58. Junan Pharmaceutical Company Information Table 59. Junan Pharmaceutical Business Overview Table 60. Junan Pharmaceutical Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Junan Pharmaceutical Medical Nuclide Products Product Portfolio Table 62. Junan Pharmaceutical Recent Development Table 63. Bayer Company Information Table 64. Bayer Business Overview Table 65. Bayer Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Bayer Medical Nuclide Products Product Portfolio Table 67. Bayer Recent Development Table 68. Siemens Company Information Table 69. Siemens Business Overview Table 70. Siemens Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Siemens Medical Nuclide Products Product Portfolio Table 72. Siemens Recent Development Table 73. Q BioMed Company Information Table 74. Q BioMed Business Overview Table 75. Q BioMed Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Q BioMed Medical Nuclide Products Product Portfolio Table 77. Q BioMed Recent Development Table 78. Progenics Pharmaceuticals Company Information Table 79. Progenics Pharmaceuticals Business Overview Table 80. Progenics Pharmaceuticals Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Progenics Pharmaceuticals Medical Nuclide Products Product Portfolio Table 82. Progenics Pharmaceuticals Recent Development Table 83. Polatom Company Information Table 84. Polatom Business Overview Table 85. Polatom Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Polatom Medical Nuclide Products Product Portfolio Table 87. Polatom Recent Development Table 88. NTP Radioisotopes Company Information Table 89. NTP Radioisotopes Business Overview Table 90. NTP Radioisotopes Medical Nuclide Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. NTP Radioisotopes Medical Nuclide Products Product Portfolio Table 92. NTP Radioisotopes Recent Development Table 93. NRG Company Information Table 94. NRG Business Overview Table 95. NRG Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. NRG Medical Nuclide Products Product Portfolio Table 97. NRG Recent Development Table 98. Novartis International AG Company Information Table 99. Novartis International AG Business Overview Table 100. Novartis International AG Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Novartis International AG Medical Nuclide Products Product Portfolio Table 102. Novartis International AG Recent Development Table 103. Nordion Company Information Table 104. Nordion Business Overview Table 105. Nordion Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Nordion Medical Nuclide Products Product Portfolio Table 107. Nordion Recent Development Table 108. Mundipharma Company Information Table 109. Mundipharma Business Overview Table 110. Mundipharma Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Mundipharma Medical Nuclide Products Product Portfolio Table 112. Mundipharma Recent Development Table 113. Monrol Company Information Table 114. Monrol Business Overview Table 115. Monrol Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Monrol Medical Nuclide Products Product Portfolio Table 117. Monrol Recent Development Table 118. Lantheus Medical Imaging, Inc. Company Information Table 119. Lantheus Medical Imaging, Inc. Business Overview Table 120. Lantheus Medical Imaging, Inc. Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Lantheus Medical Imaging, Inc. Medical Nuclide Products Product Portfolio Table 122. Lantheus Medical Imaging, Inc. Recent Development Table 123. Jubilant Life Sciences Company Information Table 124. Jubilant Life Sciences Business Overview Table 125. Jubilant Life Sciences Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Jubilant Life Sciences Medical Nuclide Products Product Portfolio Table 127. Jubilant Life Sciences Recent Development Table 128. International Isotopes Company Information Table 129. International Isotopes Business Overview Table 130. International Isotopes Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. International Isotopes Medical Nuclide Products Product Portfolio Table 132. International Isotopes Recent Development Table 133. GE Healthcare Company Information Table 134. GE Healthcare Business Overview Table 135. GE Healthcare Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. GE Healthcare Medical Nuclide Products Product Portfolio Table 137. GE Healthcare Recent Development Table 138. Eckert & Ziegler Strahlen Company Information Table 139. Eckert & Ziegler Strahlen Business Overview Table 140. Eckert & Ziegler Strahlen Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Eckert & Ziegler Strahlen Medical Nuclide Products Product Portfolio Table 142. Eckert & Ziegler Strahlen Recent Development Table 143. Curium Pharma Company Information Table 144. Curium Pharma Business Overview Table 145. Curium Pharma Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Curium Pharma Medical Nuclide Products Product Portfolio Table 147. Curium Pharma Recent Development Table 148. Cardinal Health Company Information Table 149. Cardinal Health Business Overview Table 150. Cardinal Health Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Cardinal Health Medical Nuclide Products Product Portfolio Table 152. Cardinal Health Recent Development Table 153. Bracco Imaging Company Information Table 154. Bracco Imaging Business Overview Table 155. Bracco Imaging Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. Bracco Imaging Medical Nuclide Products Product Portfolio Table 157. Bracco Imaging Recent Development Table 158. Aurobindo Pharma Company Information Table 159. Aurobindo Pharma Business Overview Table 160. Aurobindo Pharma Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 161. Aurobindo Pharma Medical Nuclide Products Product Portfolio Table 162. Aurobindo Pharma Recent Development Table 163. ANSTO Company Information Table 164. ANSTO Business Overview Table 165. ANSTO Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 166. ANSTO Medical Nuclide Products Product Portfolio Table 167. ANSTO Recent Development Table 168. Acrotech Biopharma. Company Information Table 169. Acrotech Biopharma. Business Overview Table 170. Acrotech Biopharma. Medical Nuclide Products Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 171. Acrotech Biopharma. Medical Nuclide Products Product Portfolio Table 172. Acrotech Biopharma. Recent Development Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Medical Nuclide Products Product Image Figure 2. Global Medical Nuclide Products Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medical Nuclide Products Market Size (2021-2032) & (US$ Million) Figure 4. Global Medical Nuclide Products Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Radiopharmaceuticals Image Figure 8. Radioactive Sources Image Figure 9. Medical Diagnostic Nuclides Image Figure 10. Others Image Figure 11. Global Medical Nuclide Products Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Medical Nuclide Products Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Medical Nuclide Products Sales Value Share by Type (2021-2032) Figure 14. Hematological Diseases Image Figure 15. Cardiovascular Diseases Image Figure 16. Bone and Joint Diseases Image Figure 17. Cancer Image Figure 18. Others Image Figure 19. Global Medical Nuclide Products Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Medical Nuclide Products Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Medical Nuclide Products Sales Value Share by Application (2021-2032) Figure 22. Global Medical Nuclide Products Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Medical Nuclide Products Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Medical Nuclide Products Sales Value (2021-2032) & (US$ Million) Figure 25. North America Medical Nuclide Products Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Medical Nuclide Products Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Medical Nuclide Products Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Medical Nuclide Products Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Medical Nuclide Products Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Medical Nuclide Products Sales Value (2021-2032) & (US$ Million) Figure 31. South America Medical Nuclide Products Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Medical Nuclide Products Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Medical Nuclide Products Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Medical Nuclide Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Radiopharmaceuticals
  • Radioactive Sources
  • Medical Diagnostic Nuclides
  • Others
Applications
  • Hematological Diseases
  • Cardiovascular Diseases
  • Bone and Joint Diseases
  • Cancer
  • Others
Companies covered
  • China Isotope & Radiation
  • Dongcheng Pharma
  • Eli Lilly
  • Junan Pharmaceutical
  • Bayer
  • Siemens
  • Q BioMed
  • Progenics Pharmaceuticals
  • Polatom
  • NTP Radioisotopes
  • NRG
  • Novartis International AG
  • Nordion
  • Mundipharma
  • Monrol
  • Lantheus Medical Imaging, Inc.
  • Jubilant Life Sciences
  • International Isotopes
  • GE Healthcare
  • Eckert & Ziegler Strahlen
  • Curium Pharma
  • Cardinal Health
  • Bracco Imaging
  • Aurobindo Pharma
  • ANSTO
  • Acrotech Biopharma.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Medical Nuclide Products Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Medical Nuclide Products Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Medical Nuclide Products Market Dynamics
  1. 2.1 Medical Nuclide Products Industry Trends
  2. 2.2 Medical Nuclide Products Industry Drivers
  3. 2.3 Medical Nuclide Products Industry Opportunities and Challenges
  4. 2.4 Medical Nuclide Products Industry Restraints
3 Medical Nuclide Products Market by Company
  1. 3.1 Global Medical Nuclide Products Company Revenue Ranking in 2025
  2. 3.2 Global Medical Nuclide Products Revenue by Company (2021-2026)
  3. 3.3 Global Medical Nuclide Products Company Ranking (2024-2026)
  4. 3.4 Global Medical Nuclide Products Company Manufacturing Base and Headquarters
  5. 3.5 Global Medical Nuclide Products Company Product Type and Application
  6. 3.6 Global Medical Nuclide Products Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Medical Nuclide Products Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Medical Nuclide Products Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Medical Nuclide Products Market by Type
  1. 4.1 Medical Nuclide Products Type Introduction
  2. 4.1.1 Radiopharmaceuticals
  3. 4.1.2 Radioactive Sources
  4. 4.1.3 Medical Diagnostic Nuclides
  5. 4.1.4 Others
  6. 4.2 Global Medical Nuclide Products Sales Value by Type
  7. 4.2.1 Global Medical Nuclide Products Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Medical Nuclide Products Sales Value by Type (2021-2032)
  9. 4.2.3 Global Medical Nuclide Products Sales Value Share by Type (2021-2032)
5 Medical Nuclide Products Market by Application
  1. 5.1 Medical Nuclide Products Application Introduction
  2. 5.1.1 Hematological Diseases
  3. 5.1.2 Cardiovascular Diseases
  4. 5.1.3 Bone and Joint Diseases
  5. 5.1.4 Cancer
  6. 5.1.5 Others
  7. 5.2 Global Medical Nuclide Products Sales Value by Application
  8. 5.2.1 Global Medical Nuclide Products Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Medical Nuclide Products Sales Value by Application (2021-2032)
  10. 5.2.3 Global Medical Nuclide Products Sales Value Share by Application (2021-2032)
6 Medical Nuclide Products Regional Value Analysis
  1. 6.1 Global Medical Nuclide Products Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Medical Nuclide Products Sales Value by Region (2021-2032)
  3. 6.2.1 Global Medical Nuclide Products Sales Value by Region: 2021-2026
  4. 6.2.2 Global Medical Nuclide Products Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Medical Nuclide Products Sales Value (2021-2032)
  7. 6.3.2 North America Medical Nuclide Products Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Medical Nuclide Products Sales Value (2021-2032)
  10. 6.4.2 Europe Medical Nuclide Products Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Medical Nuclide Products Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Medical Nuclide Products Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Medical Nuclide Products Sales Value (2021-2032)
  16. 6.6.2 South America Medical Nuclide Products Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Medical Nuclide Products Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Medical Nuclide Products Sales Value Share by Country, 2025 VS 2032
7 Medical Nuclide Products Country-level Value Analysis
  1. 7.1 Global Medical Nuclide Products Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Medical Nuclide Products Sales Value by Country (2021-2032)
  3. 7.2.1 Global Medical Nuclide Products Sales Value by Country (2021-2026)
  4. 7.2.2 Global Medical Nuclide Products Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Medical Nuclide Products Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Medical Nuclide Products Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Medical Nuclide Products Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China Isotope & Radiation
  2. 8.1.1 China Isotope & Radiation Company Information
  3. 8.1.2 China Isotope & Radiation Business Overview
  4. 8.1.3 China Isotope & Radiation Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  5. 8.1.4 China Isotope & Radiation Medical Nuclide Products Product Portfolio
  6. 8.1.5 China Isotope & Radiation Recent Developments
  7. 8.2 Dongcheng Pharma
  8. 8.2.1 Dongcheng Pharma Company Information
  9. 8.2.2 Dongcheng Pharma Business Overview
  10. 8.2.3 Dongcheng Pharma Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dongcheng Pharma Medical Nuclide Products Product Portfolio
  12. 8.2.5 Dongcheng Pharma Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Medical Nuclide Products Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Junan Pharmaceutical
  20. 8.4.1 Junan Pharmaceutical Company Information
  21. 8.4.2 Junan Pharmaceutical Business Overview
  22. 8.4.3 Junan Pharmaceutical Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Junan Pharmaceutical Medical Nuclide Products Product Portfolio
  24. 8.4.5 Junan Pharmaceutical Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Medical Nuclide Products Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Siemens
  32. 8.6.1 Siemens Company Information
  33. 8.6.2 Siemens Business Overview
  34. 8.6.3 Siemens Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Siemens Medical Nuclide Products Product Portfolio
  36. 8.6.5 Siemens Recent Developments
  37. 8.7 Q BioMed
  38. 8.7.1 Q BioMed Company Information
  39. 8.7.2 Q BioMed Business Overview
  40. 8.7.3 Q BioMed Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Q BioMed Medical Nuclide Products Product Portfolio
  42. 8.7.5 Q BioMed Recent Developments
  43. 8.8 Progenics Pharmaceuticals
  44. 8.8.1 Progenics Pharmaceuticals Company Information
  45. 8.8.2 Progenics Pharmaceuticals Business Overview
  46. 8.8.3 Progenics Pharmaceuticals Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Progenics Pharmaceuticals Medical Nuclide Products Product Portfolio
  48. 8.8.5 Progenics Pharmaceuticals Recent Developments
  49. 8.9 Polatom
  50. 8.9.1 Polatom Company Information
  51. 8.9.2 Polatom Business Overview
  52. 8.9.3 Polatom Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Polatom Medical Nuclide Products Product Portfolio
  54. 8.9.5 Polatom Recent Developments
  55. 8.10 NTP Radioisotopes
  56. 8.10.1 NTP Radioisotopes Company Information
  57. 8.10.2 NTP Radioisotopes Business Overview
  58. 8.10.3 NTP Radioisotopes Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  59. 8.10.4 NTP Radioisotopes Medical Nuclide Products Product Portfolio
  60. 8.10.5 NTP Radioisotopes Recent Developments
  61. 8.11 NRG
  62. 8.11.1 NRG Company Information
  63. 8.11.2 NRG Business Overview
  64. 8.11.3 NRG Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  65. 8.11.4 NRG Medical Nuclide Products Product Portfolio
  66. 8.11.5 NRG Recent Developments
  67. 8.12 Novartis International AG
  68. 8.12.1 Novartis International AG Company Information
  69. 8.12.2 Novartis International AG Business Overview
  70. 8.12.3 Novartis International AG Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novartis International AG Medical Nuclide Products Product Portfolio
  72. 8.12.5 Novartis International AG Recent Developments
  73. 8.13 Nordion
  74. 8.13.1 Nordion Company Information
  75. 8.13.2 Nordion Business Overview
  76. 8.13.3 Nordion Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Nordion Medical Nuclide Products Product Portfolio
  78. 8.13.5 Nordion Recent Developments
  79. 8.14 Mundipharma
  80. 8.14.1 Mundipharma Company Information
  81. 8.14.2 Mundipharma Business Overview
  82. 8.14.3 Mundipharma Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Mundipharma Medical Nuclide Products Product Portfolio
  84. 8.14.5 Mundipharma Recent Developments
  85. 8.15 Monrol
  86. 8.15.1 Monrol Company Information
  87. 8.15.2 Monrol Business Overview
  88. 8.15.3 Monrol Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Monrol Medical Nuclide Products Product Portfolio
  90. 8.15.5 Monrol Recent Developments
  91. 8.16 Lantheus Medical Imaging, Inc.
  92. 8.16.1 Lantheus Medical Imaging, Inc. Company Information
  93. 8.16.2 Lantheus Medical Imaging, Inc. Business Overview
  94. 8.16.3 Lantheus Medical Imaging, Inc. Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Lantheus Medical Imaging, Inc. Medical Nuclide Products Product Portfolio
  96. 8.16.5 Lantheus Medical Imaging, Inc. Recent Developments
  97. 8.17 Jubilant Life Sciences
  98. 8.17.1 Jubilant Life Sciences Company Information
  99. 8.17.2 Jubilant Life Sciences Business Overview
  100. 8.17.3 Jubilant Life Sciences Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Jubilant Life Sciences Medical Nuclide Products Product Portfolio
  102. 8.17.5 Jubilant Life Sciences Recent Developments
  103. 8.18 International Isotopes
  104. 8.18.1 International Isotopes Company Information
  105. 8.18.2 International Isotopes Business Overview
  106. 8.18.3 International Isotopes Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  107. 8.18.4 International Isotopes Medical Nuclide Products Product Portfolio
  108. 8.18.5 International Isotopes Recent Developments
  109. 8.19 GE Healthcare
  110. 8.19.1 GE Healthcare Company Information
  111. 8.19.2 GE Healthcare Business Overview
  112. 8.19.3 GE Healthcare Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  113. 8.19.4 GE Healthcare Medical Nuclide Products Product Portfolio
  114. 8.19.5 GE Healthcare Recent Developments
  115. 8.20 Eckert & Ziegler Strahlen
  116. 8.20.1 Eckert & Ziegler Strahlen Company Information
  117. 8.20.2 Eckert & Ziegler Strahlen Business Overview
  118. 8.20.3 Eckert & Ziegler Strahlen Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Eckert & Ziegler Strahlen Medical Nuclide Products Product Portfolio
  120. 8.20.5 Eckert & Ziegler Strahlen Recent Developments
  121. 8.21 Curium Pharma
  122. 8.21.1 Curium Pharma Company Information
  123. 8.21.2 Curium Pharma Business Overview
  124. 8.21.3 Curium Pharma Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Curium Pharma Medical Nuclide Products Product Portfolio
  126. 8.21.5 Curium Pharma Recent Developments
  127. 8.22 Cardinal Health
  128. 8.22.1 Cardinal Health Company Information
  129. 8.22.2 Cardinal Health Business Overview
  130. 8.22.3 Cardinal Health Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Cardinal Health Medical Nuclide Products Product Portfolio
  132. 8.22.5 Cardinal Health Recent Developments
  133. 8.23 Bracco Imaging
  134. 8.23.1 Bracco Imaging Company Information
  135. 8.23.2 Bracco Imaging Business Overview
  136. 8.23.3 Bracco Imaging Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Bracco Imaging Medical Nuclide Products Product Portfolio
  138. 8.23.5 Bracco Imaging Recent Developments
  139. 8.24 Aurobindo Pharma
  140. 8.24.1 Aurobindo Pharma Company Information
  141. 8.24.2 Aurobindo Pharma Business Overview
  142. 8.24.3 Aurobindo Pharma Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Aurobindo Pharma Medical Nuclide Products Product Portfolio
  144. 8.24.5 Aurobindo Pharma Recent Developments
  145. 8.25 ANSTO
  146. 8.25.1 ANSTO Company Information
  147. 8.25.2 ANSTO Business Overview
  148. 8.25.3 ANSTO Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  149. 8.25.4 ANSTO Medical Nuclide Products Product Portfolio
  150. 8.25.5 ANSTO Recent Developments
  151. 8.26 Acrotech Biopharma.
  152. 8.26.1 Acrotech Biopharma. Company Information
  153. 8.26.2 Acrotech Biopharma. Business Overview
  154. 8.26.3 Acrotech Biopharma. Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Acrotech Biopharma. Medical Nuclide Products Product Portfolio
  156. 8.26.5 Acrotech Biopharma. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst